These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19531281)

  • 1. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.
    Alvarez XA; Sampedro C; Cacabelos R; Linares C; Aleixandre M; García-Fantini M; Moessler H
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):867-72. PubMed ID: 19531281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Ruether E; Husmann R; Kinzler E; Diabl E; Klingler D; Spatt J; Ritter R; Schmidt R; Taneri Z; Winterer W; Koper D; Kasper S; Rainer M; Moessler H
    Int Clin Psychopharmacol; 2001 Sep; 16(5):253-63. PubMed ID: 11552768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.
    Alvarez A; Cacabelos R; Sanpedro C; García-Fantini M; Aleixandre M
    Neurobiol Aging; 2007 Apr; 28(4):533-6. PubMed ID: 16569464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.
    Ruether E; Alvarez XA; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):265-75. PubMed ID: 12456069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
    Asthana S; Craft S; Baker LD; Raskind MA; Birnbaum RS; Lofgreen CP; Veith RC; Plymate SR
    Psychoneuroendocrinology; 1999 Aug; 24(6):657-77. PubMed ID: 10399774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrolysin in Alzheimer's disease.
    Antón Álvarez X; Fuentes P
    Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.
    Muresanu DF; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):277-85. PubMed ID: 12456070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease.
    Diniz BS; Teixeira AL; Ojopi EB; Talib LL; Mendonça VA; Gattaz WF; Forlenza OV
    J Alzheimers Dis; 2010; 22(4):1305-11. PubMed ID: 20930310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration.
    Muresanu DF; Alvarez XA; Moessler H; Buia M; Stan A; Pintea D; Moldovan F; Popescu BO
    J Neurol Sci; 2008 Apr; 267(1-2):112-9. PubMed ID: 18048059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.